Small-molecule NNMT inhibitor · Fact sheet

5-Amino-1MQ

Also known as 5A1MQ · 5-amino-1-methylquinolinium

5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT. Mouse studies found changes in fat mass and metabolism, but the cited evidence does not establish human weight-loss benefits or a human safety profile.

Preclinical researchMostly animal or lab research

What is 5-Amino-1MQ?

NNMT is nicotinamide N-methyltransferase, an enzyme involved in cellular metabolism. 5-Amino-1MQ is not a peptide and should not be equated with every compound that inhibits NNMT.

Benefits & claims

Fat loss, higher energy, and changes in NAD metabolism generate interest. Mechanistic overlap with NAD pathways does not prove an anti-aging benefit.

What the evidence supports

  • Mouse studies reported less fat accumulation and improved metabolic measures.
  • A 28-day mouse study found changes in glucose handling and liver fat; these are preclinical outcomes.
Research areas
  • NNMT inhibition
  • Obesity models
  • Liver and metabolic biomarkers

Dosage & frequency

No established human regimen

5-Amino-1MQ is an experimental small-molecule NNMT inhibitor, not a peptide. Reviewed evidence does not establish a human treatment dose or frequency.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Mouse dose experiments cannot be converted into a supported human regimen.

Interactions & precautions

  • Human drug-interaction studies have not established a compatibility profile for this preclinical NNMT inhibitor.

What is still unresolved

  • Human pharmacokinetics, repeated-use safety, and interactions remain unestablished.

Side effects & risks

  • The reviewed evidence does not provide a validated list or frequency of human side effects.
  • Short animal studies cannot exclude human organ toxicity, interactions, or long-term harms.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

The principal studies use diet-induced obese mice and cultured cells. Different experiments include dietary changes, so their results cannot all be attributed to the compound alone.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Appetite: reported experiences

Mixed account · personal report

Subtle body changes, emotional flatness, unchanged energy

Over about a month, a person dieting and exercising reported less constant hunger and perceived changes in body shape, but little scale movement. Energy and gym performance stayed similar; emotions later felt muted.

Reported use in this account

Product
Product described as oral 5-Amino-1MQ capsules
Amount
50 mg per day; a brief 75 mg trial was also described
Frequency
Daily, divided between morning and early afternoon
Route
Oral
Duration
About one month

Diet, activity and expectations confound the experience. Body composition and product contents were not verified; the poster also questioned whether dieting explained the emotional change.

Read the month-long account

Approval status

5-Amino-1MQ has no FDA-approved therapeutic use. The cited cell and mouse studies support preclinical research, not a proven human weight-loss intervention.

Preclinical compound; no FDA-approved use

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Human efficacy and clinically meaningful outcomes
  • Human pharmacokinetics and interactions
  • Long-term safety and product comparability

Summary

5-Amino-1MQ is a research lead for metabolism, with human benefits and harms still unresolved.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedSelective NNMT inhibitors in cells and obese mice

    Mechanistic experiments and an 11-day mouse obesity experiment.

  2. pubmedNNMT inhibition, diet, and the mouse microbiome

    Diet and compound effects studied together in obese mice.

  3. pubmedNNMT inhibition and obesity-related metabolic dysfunction

    28-day mouse study of body composition, glucose handling, and liver findings.

How we assess sources · Suggest a correction